AIM2 co‐immunization helps CD8(+) T‐cell production and amends CVB3 stimulated chronic myocarditis, AIM2‐adjuvanted viral capsid protein 1 (VP1) vaccine for CVB3 therapy, AIM‐2 as antigen‐specific active immunotherapy for glioma patients. Here, CD8A is linked to central nervous system cancer.